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Abstract  
TITLE OF THE ABSTRACT: Predictors of mortality and morbidity in soft tissue infections of the 
lower limb 
OBJECTIVES: To assess the various parameters that predicts the mortality and morbidity in 
patients with soft tissue infections of the lower limb. 
METHODS: A nested case control study was designed with a sample size of fifty five in each arm. 
Patients were recruited and based on the outcome they were grouped under one of the two arms: 
non mortality, non morbidity arm and mortality, morbidity arm. From the data collected, 
univariate and multivariate analysis were done to find significant variables predicting mortality 
and morbidity. 
RESULTS: The significant variables that predict morbidity in patients with soft tissue infections are 
neutrophilia, low sodium and elevated temperature at presentation. The significant variables that 
predict mortality in patients with soft tissue infections are diabetes mellitus, requirement of 
ventilator support and requirement of dialysis. 
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1. Introduction 
Soft tissue infections are known to mankind from the times of Hippocrates. Soft tissue infections 
(STI) are infections of the non skeletal tissue i.e. exclusive of bone, ligaments, cartilage and fibrous 
tissue.  
Soft tissue infection affecting the lower extremity comprises of 50% of all soft tissue infection and 
is one of the most common acute surgical conditions resenting to the emergency department. The 
incidence of soft tissue infection is about 0.04 per 1000 population in the western world. However 
the incidence is higher in the developing countries. Despite advances in treatment, the morbidity 
and mortality rates of soft tissue infection are still high at 25-35%.  
There are various factors associated with these infections. Most common factor is diabetes 
mellitus. The various other factors associated with STI’s are drug abuse, obesity, 
immunosuppression, recent surgery, malignancy, trauma etc.  
Soft tissue infections are of two subtypes: necrotising and non-necrotising infections. Based on the 
depth of infection it can be further classified as cellulitis, adipositis, fasciitis and myositis. 
When classified according to the microbial source of infection, soft tissue infection can be grouped as  
Type I due to polymicrobial source of infection 
Type II due to monomicrobial source of infection 
Type III due to vibrio vulnificus 
Type IV due to fungus 
Most common organisms causing soft tissue infections are Group A Streptococci in the developed 
countries. However polymicrobial source is the most common infection in the developing countries.  
Clinical presentation can range from superficial erythema, induration and oedema as in non necrotising 
infection to myonecrosis as in necrotising soft tissue infections. Patient may also have systemic illness if 
bacteraemia is present. 
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The microorganisms enter the tissue through external injury or directly from a perforated viscus.  These 
organisms track along the subcutaneous planes producing endotoxins and exotoxins that cause ischaemia 
of tissues leading to liquefactive necrosis and often systemic illness. Local inflammation causes thrombosis 
of the capillaries causing skin necrosis. Infections can spread as fast as 1 – 4 inch per hour with little 
external changes. As these tissues are necrotic, there is not enough antibiotic supply to this tissue, hence 
surgical debridement is the mainstay of treatment. An inexperienced surgeon may not identify these skin 
lesions to be significant causing considerable delay in diagnosis. This leads to systemic illness causing high 
morbidity and mortality.  
There are no standard criteria to predict soft tissue infection and its severity. The LRINEC (Laboratory Risk 
Indicator for Necrotising fasciitis) score is based on laboratory indicators. This was a retrospective study 
done on a subset of patients with type III infection which is very uncommon in our setting.  
There were various factors identified to predict morbidity and mortality in soft tissue infection but 
review of studies done in soft tissue infections of the lower limb showed that they were all 
retrospective studies with varying conclusions and limitations. In addition, there are no studies 
reported from Indian institutions looking at this common but significant problem.  
Hence we need an objective method to predict the severity of soft tissue infection to initiate the 
appropriate treatment as early as possible to reduce the morbidity and mortality associated with 
this disease. 
Hence we propose this prospective study to analyse various variables (historical, clinical and 
laboratory) to identify predictors of morbidity and mortality in soft tissue infections.  
These variables can be used to assess the severity of infection. If significant, appropriate therapy can then 
be initiated to improve outcomes of patients suffering from this condition.  
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2. Aim of the study 
To assess the various parameters that predict the mortality and morbidity in patients with soft tissue 
infections of the lower limb. 
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3. Review of literature 
3.1.0. Definition: 
Soft tissue infections are defined as infections of the non skeletal tissue i.e. exclusive of bone, ligaments, 
cartilage and fibrous tissue(1). 
3.2.0. History: 
Soft tissue infections are known to mankind from the days of Hippocrates(2). Later it was described as 
hospital gangrene by British surgeons.  Dr. Joseph Jones described the disorder in a large group of patients 
with a mortality of 46%.  This was later described by French and American surgeons. This was called by 
different names as necrotising erysipelas, Streptococcal gangrene, Suppurative fasciitis. The term 
necrotising soft tissue infections was coined by Dr. Wilson in 1951(2). Necrotising soft tissue infection 
(NSTI) now represents a disease spectrum that ranges from necrotising cellulitis to myonecrosis. 
3.3.0. Epidemiology: 
The overall incidence of necrotising soft tissue infection in the United States was reported as 0.04/1000 
people or 1000/year (2)(3). There are about 3.5 cases of invasive group A streptococcus infections per 
100,000 persons in the United States; necrotising infections make up approximately 6 percent of these 
cases (4). In New Zealand, the incidence increased from 0.18 to 1.68 per 100,000 per year between 1990 
and 2006 (5). In New Zealand the prevalence was similar among different ethnic groups, but the mortality 
was greater among older adults and native Pacific Islanders (5). There were also case reports of 
Clostridium sordellii and C. novyii, causing necrotising soft tissue infections in drug abusers (6). Most of 
the cases were community acquired whereas 20 percent was hospital acquired.  
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Despite centuries of knowledge, the cumulative mortality rate of soft tissue infections are still around 
25%-35% especially in the necrotising subgroup (3, 7). There needs to be a high index of suspicion for 
appropriate treatment to be instituted. Delayed recognition is one of the major reasons for increased 
mortality(7).  
Soft tissue infections are more common in the lower extremity, with 50% of infections in the foot and 39% 
in the leg (7). The other common sites of soft tissue infections are scrotum, head and neck, upper 
extremity.  
There are no studies from India demonstrating the disease burden. In the Christian Medical College and 
Hospital, a retrospective review of charts in a single unit of the Division of surgery, revealed that there 
were 71 cases of lower limb soft tissue infections in one year with a morbidity of 40.8 percent and 
mortality of 5.6 percent. 
3.3.1. Associated factors: 
There is a higher predilection of this condition in men(8). Diabetes mellitus is also found to have a strong 
relationship with soft tissue infections, with 75% of the patients with soft tissue infections having diabetes 
mellitus(8). There is a preceding history of trauma in 40% of patients(8). 
The risk factors for necrotising soft tissue infection include diabetes, drug use, obesity, 
immunosuppression, recent surgery, hepatitis C, malignancy and traumatic wounds(9)(10). 
Other risk factors include chronic renal failure, HIV, alcohol abuse, blunt or penetrating trauma, insect 
bites, surgical incisions, indwelling catheters, chicken pox, vesicles, and perforation of the gastrointestinal 
tract(2). 
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3.4.0. Classification: 
Soft tissue infections can be classified by various means. 
They can be based on necrosis, anatomical, depth of infection and microbiological pattern of infection (2). 
Soft tissue infections are classified into two subtypes based on necrosis of the tissues involved as 
necrotising and non-necrotising infections(2).  
3.4.1. Based on depth: 
Based on the depth of infection it can be classified as cellulitis, erysipelas, impetigo, adipositis, fasciitis and 
myositis(2). 
a) Cellulitis: 
Cutaneous infections include cellulitis, erysipelas, and impetigo. All these are considered to be different 
presentations of the same condition. Cellulitis means inflammation of the cells just beneath the skin 
surface. This presents as a painful swelling with associated erythema and tenderness(11). 
b) Adipositis: 
Adipositis is defined as inflammation of the adipose tissue. This is also called as panniculitis(12). 
c) Necrotising fasciitis: 
Necrotising fasciitis is defined as soft tissue infection which involves the superficial fascia which also 
involves the subcutaneous tissue with thrombosis of the cutaneous microcirculation(1, 3). 
d) Myonecrosis: 
Myonecrosis or necrotising myonecrosis is a rare entity and is defined as inflammation and death of 
muscle tissues(2). This has been associated with high mortality ranging from 80-100 percent(13). 
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3.4.2. Microbial source of infection: 
Soft tissue infections can be classified according to the organisms isolated on culture(2)(14). 
a) Type I STI: 
These are due to polymicrobial source of infection. The most common organisms are isolated in this type 
of infection are Streptococci, Bacteroides, E.Coli, Enterobacter, Klebsiella, Proteus, Acenetobacter 
baumanii, Enterococcus spp, Pseudomonas aeruginosa. 
b) Type II STI: 
These are due to monomicrobial source of infection. The most common organism isolated in this type of 
infection is group A Streptococci and Staphylococcus aureus.  
c) Type III STI: 
These infections are caused by Vibrio vulnificus. This infection is more common in coastal regions of the 
tropics.  
d) TYPE IV STI: 
These infections are caused due to fungus. The most common organisms are Candida, Zygomycotic, 
Mucor and Rhizopus spp. 
3.5.0. Pathophysiology: 
The microorganisms enter the skin or subcutaneous tissue through external injury or directly from a 
perforated viscus.  These organisms track along the subcutaneous planes producing endotoxins and 
exotoxins that cause ischemia of tissues leading to liquefactive necrosis and often systemic illness. 
Infections can spread as fast as 1 – 4 inch per hour with little external changes(15)(7). 
The various exotoxins produced enhance microbial virulence and potentiate the necrosis of the tissues. 
Increased expression of vimentin potentiates the adherence of group A streptococcus to the tissue and  
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localises the infection(16). Staphylococcus aureus and Streptococci produce surface proteins M-1 and M-
3, exotoxins A, B, C, streptolysin O, and super antigen. The M proteins help the organisms to adhere to 
tissues and prevent phagocytosis. Toxins A and B damage the endothelium and cause loss of micro 
vascular integrity. This leads to transfer of plasma, oedema of the tissues and impaired blood flow at the 
capillary level(17). These toxins, along with streptolysin O, stimulate CD4 cells and macrophages to 
produce tumour necrosis factor, interleukin-1, and interleukin-6 which potentiate a systemic inflammatory 
response. Systemic inflammatory response can progress to septic shock, multisystem organ dysfunction, 
and death (15). 
Vibrio vulnificus has capsular polysaccharide which prevents phagocytosis. This along with toxins such as 
hemolysin, help the organism to overcome the host’s immune response(18).  
Tumour necrosis factor, released by the host’s immune response also injures the vascular endothelium by 
stimulating neutrophil degranulation. Super antigens stimulate T cells directly, activating complement, the 
bradykinin-kallikrein system, and the coagulation cascade, thereby worsening small vessel thrombosis and 
tissue ischaemia(19). Thrombosis is caused by the local hyper-coagualable state, platelet-neutrophil 
plugging of vessels and increased interstitial pressure together resulting in decreased capillary blood flow 
to end tissue(19). All these lead to a common pathway leading to tissue ischaemia, impeding the oxidative 
destruction of bacteria and prevent the adequate delivery of antibiotics. 
Although thrombosis of vessels supplying the skin is the  key feature in the pathophysiology of NSTI, the 
extent of tissue damage may be more, as thrombosis of large number of  dermal capillaries is needed for 
skin changes to occur(2). 
Super antigens cause massive activation of T-cells, cytokine release, tissue damage and shock. Shock is due 
to the capillary leak syndrome causing hypotension and disseminated intravascular coagulation due to 
super antigen production. Hypoalbuminaemia ensues, with oedema, hypotension and respiratory distress 
syndrome(14).  
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3.6.0. Microbiology: 
Necrotising soft tissue infection can be classified into four types based on the microbiological source of 
infection. They are  
Type I STI Due to polymicrobial source of infection 
Type II STI Due to monomicrobial source of infection 
Type III STI Due to Vibrio vulnificus 
Type IV Due to fungus 
 
3.6.1. Type I STI: 
Type I STI is due to polymicrobial source which comprises of 55-75 percent of cases. The common 
organisms in Type I STI isolated are anaerobic Streptococci, Bacteroides, Clostridium, Peptostreptococcus, 
E.Coli, Enterobacter, Klebsiella, Proteus, Acenetobacter baumanii, Enterococcus fecalis, Streptococcal 
viridians,  Acinetobacter baumannii, and Pseudomonas aeroginosa(9)(3)(7). 
Type I STI of head and neck involves mouth anaerobes like Fusobacteria, anaerobic Streptococci and 
Spirochetes(9). 
Fournier’s gangrene is a Type I STI which may involve E. coli, Klebsiella, Enterococci along with 
Bacteroides, Fusobacterium, Clostridium, anaerobic or microaerophilic Streptococci(7). 
3.6.2. Type II STI: 
Type II STI is also known as Group A Streptococcal gangrene which has a monomicrobial source of 
infection which comprises of 20-30 percent of cases. The most common organism in the type is group A 
streptococci or other beta-haemolytic streptococci. They are usually isolated alone or with Staphylococcus 
aureus. There are also reports of community acquired methicillin resistant Staphylococcus aureus (MRSA) 
as a cause of necrotising soft tissue infections(10).  
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The other organisms that were isolated alone were Klebsiella pneumoniae, Hemophilus influenza and 
Vibrio species(3)(20). 
Blood cultures of patient with STI’s were predominantly grew Methicillin sensitive and Methicillin resistant 
Staphylococcus aureus and Vibrio species. There were also reports of E.coli isolated in blood(3). 
3.6.3. Type III STI: 
Type III STI’s are caused by Vibrio vulnificus which were responsible for 0.53 cases per 100 000 in Hong 
Kong in late 1990’s. This is associated with raw oyster ingestion and patients with iron overload. Wound 
contamination with sea water accounts for 25 percent of these cases. Digestive enzymes contribute for its 
high mortality which is about 30 percent(20). 
3.6.4. Type IV STI: 
Type IV STI’s are due to fungal infection and include STI’s due Candida, Zygomycotic, Mucor and Rhizopus 
spp.  Candida usually affects people who are immunocompromised while others can affect 
immunocompetent people. Fungal infections are usually associated with trauma(14). 
Presence of Vibrio species and fungus in wound culture and presence of group A Streptococcus, 
Aeromonas species and Vibrio species in blood cultures are associated with high mortality(3). 
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3.7.0. Clinical presentation: 
The clinical presentation depends on the type of infection. It can range from superficial cellulitis with no 
systemic symptoms to necrotising infection which can be life threatening. 
3.7.1. Cellulitis: 
Cellulitis usually presents with erythema, pain, swelling, tenderness and local warmth. This may have 
systemic features of infection. Whereas necrotising cellulitis presents with thin, dark, sometimes foul-
smelling wound drainage and necrosis of the skin.  Crepitus may be observed in the skin (21). 
3.7.2. Adipositis: 
An area of skin involved with adipositis feels thickened and woody to touch. It may or may not 
demonstrate discolouration of the overlying skin. There may be reddening or brownish pigmentation. 
Associated with areas of tenderness. Most often, the affected area appear as raised nodules or lumps 
under the skin, but may be a plaque or large flat area of thickened skin. When the inflammation has 
settled, a depression in the skin may be left behind temporarily or permanently. 
3.7.3. Necrotising fasciitis: 
Necrotising fasciitis is an infection of the fascia and is more prone to destruction due to its poor blood 
supply. Underlying muscles and superficial tissue involvement is less in the initial period. Pain is out of 
proportion to the signs. Within 1-3 days the overlying tissues are also affected because of infection and 
thrombosis of vessels. This leads to cutaneous changes with appearance of bullae (containing thick pink or 
purple fluid) and frank cutaneous gangrene. The tenderness is less in the involved region as it becomes 
anaesthetic because of thrombosis of small blood vessels and destruction of superficial nerves in the 
subcutaneous tissue. The development of anaesthesia precede skin changes and hence helps in 
identification of necrotising fasciitis(2,14). 
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3.7.4. Myositis: 
Necrotising myonecrosis has similar presentation as necrotising fasciitis. Clostridial myonecrosis is most 
common and is associated with trauma. Crepitus is present at the site of infection with associated 
systemic toxicity. Spontaneous myonecrosis is associated with more aero tolerant bacteria. Crepitus may 
not be present in this type of infection(22). 
Non necrotising myositis presents as a painful swelling with induration with no evidence of necrosis 
predominantly involving the quadriceps. This is mostly due to a viral aetiology(22).  
3.7.5. Compartment syndrome: 
All the above infections can have marked swelling and oedema. This leads to increase in the tissue 
pressure which exceeds perfusion pressure within a closed muscle compartment. This leads to impaired 
venous flow and accumulation of waste products resulting in pain and paraesthesia due to nerve injury. 
Delayed recognition leads to myonecrosis.   
3.7.6. Other clinical presentations: 
Patients usually have fever, tachycardia, and features of systemic toxicity, with temperature elevation in 
the range of 38.9° to 40.5°C (102° to 105°F).  Other symptoms include malaise, myalgias, diarrhoea, and 
anorexia. Patients may present with low urine output due to renal failure or altered sensorium caused by 
septicaemia. Hypotension may be present initially or develop with disease progression.   
Septic shock is one of the common presentations in the Emergency Department which requires aggressive 
resuscitation with fluids, antibiotics and source control. Patients presenting with shock have a high 
morbidity. However hypotension on admission did not  influence survival(8). 
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3.8.0. Diagnosis: 
The diagnosis of soft tissue infection is a clinical decision but most often missed due to its varied 
presentation.  
A high clinical suspicion along with a detailed history and a thorough examination is required to avoid a 
delay in diagnosis. Pain is out of proportion and general unwellness of patient should point to a diagnosis 
of soft tissue infection in the deeper planes. History should involve questions regarding recent overseas 
travel, seafood ingestion, trivial trauma, insect bites etc. They also should involve co morbid factors like 
diabetes mellitus, steroid abuse, drug abuse etc.  
Examination should be comprehensive to identify features of systemic inflammatory response syndrome 
(tachycardia, tachypnoea, fever) and skin changes. This may include mild erythema to frank necrosis of the 
tissues with haemorrhagic bullae and anaesthesia. The extent of the tissues involved need to be identified 
as it helps in demarcating the surgical margin of debridement(14,23). 
‘Finger test’ is a bed side test which involves an incision of 2 cm under local anaesthesia and inspection of 
the fascia which in NSTI will be swollen and grey with lack of bleeding and contractility. If ‘dishwater’ ﬂuid 
is found and the index ﬁnger dissects the subcutaneous tissue off the deep fascia easily along the tissue 
plane, the ﬁnger test is considered positive(20). 
Compartment pressure monitoring can be done to diagnose acute compartment syndrome. Normal 
compartment pressure at rest is 30-45 mm of Hg. Any compartment pressure more than 30 mm of Hg 
needs emergency fasciotomy. When the fasciotomy was delayed more than 12 hours, only 8% had normal 
function of the limb. 
Gram staining of the sample will help in identifying the organisms and starting on appropriate antibiotic 
therapy. 
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Laboratory investigation may reveal leucocytosis or leucopoenia. Leucocytosis is usually associated with 
polymicrobial organisms and Streptococcal infection. Staphylococcal infections may have leucopoenia(20). 
Decreasing haemoglobin may suggest an intravascular haemolysis due to sepsis. 
Acute renal failure is usually a sequelae in severe sepsis. Necrotising soft tissue infections may have 
elevated CRP and creatine kinase. Elevated creatine kinase of more than 600u/l is highly specific for 
adjacent muscle involvement.  
There may be associated hypocalcaemia, hypoalbuminemia and hyponatremia due to sepsis(2,14). 
Severe metabolic acidosis with elevated serum lactate and hyponatremia is highly predictive of mortality. 
The mortality rate is as high as 32 percent when serum lactate levels are more than 6 mmol/l and sodium 
of  less than 135 mg/L(24). 
 A tissue biopsy will help in diagnosis of necrotising fasciitis. This will reveal underlying thrombi, 
polymorphic infiltrates and microorganisms(14)(25). 
Radiological imaging like plain radiographs, plain computerised tomogram, and magnetic resonance 
imaging help in identifying gas in the tissue planes which is highly specific for necrotising soft tissue 
infections. Ultrasonography is helpful in detecting localised abscess but not studied extensively in 
NSTI’s(26). MRI and CT will detect thickened fascial plane which is highly sensitive but less specific(2). 
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3.9.0. Staging and scoring systems: 
3.9.1. For diagnosis: 
The diagnosis of necrotising soft tissue infection is crucial as surgical treatment is to be initiated at the 
earliest. Most often the morbidity and mortality is due to delay in the treatment as diagnosis was missed 
out. The diagnosis of necrotising soft tissue infection was correct in only about 38 percent(2).  
3.9.2. Clinical staging: 
Wang et al described a staging system based solely on clinical examination and skin changes in the 
progression of the disease(27). 
The various stages are 
Stage I 
 
Early stage; Tenderness to palpation (extending beyond the 
apparent area of skin involvement), erythema, swelling and calor  
Stage II Intermediate stage; blister or bullae formation with serous discharge 
Stage III Late stage; Crepitus, skin anaesthesia and skin necrosis with dusky discoloration 
The initial stage may be indistinguishable from non necrotising soft tissue infection. But as the disease 
progresses the diagnosis is to be made at the earliest because delay in identification leads to increased 
mortality rates(27). 
The mortality described in each stage according to Wang et al is  
Stage I 7.1 percent 
Stage II 14.2 percent 
Stage III 47 percent 
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3.9.3. LRINEC score: 
Wong et al described a scoring system, LRINEC score which includes laboratory parameters for predicting 
the possibility of necrotising soft tissue infections(24).   
Variable Value 
 
Score 
C-reactive protein 
(mg/dL) 
<150 
 
0 
>150 
 
4 
Total white blood cell 
count (/mm3) 
<15 
 
0 
15125 
 
1 
>25 
 
2 
Haemoglobin (g/dL) >13.5 
 
0 
11-13.5 
 
1 
<11 
 
2 
Sodium (mmol/L) >=135 
 
0 
<135 
 
2 
Creatinine (mmol/L) <141 
 
0 
>141 
 
2 
Glucose (mmol/L) <10 
 
0 
>10 
 
1 
    
This  score only includes  laboratory parameters. Any score of more than or equal to 6 should raise a 
suspicion and a score of more than 8 strongly predicts necrotising soft tissue infection(24). 
Any patient with a score of 5 or less can be treated with antibiotic. Patient with score more than 8 should 
undergo surgical treatment whereas patients with a score of 6 or 7 need further assessment.  
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3.9.4. For prognostication: 
Anaya et al suggested a scoring system for prediction of mortality(28). This system includes  
Variable (on admission) Value 
 
Number of points 
Heart rate >110 bpm 
 
1 
Temperature <36o C 
 
1 
Serum creatinine >1.5 mg/dl 
 
1 
Age >50 years 
 
3 
White blood cells >40,000/mcL 
 
3 
Hematocrit >50% 
 
3 
 
The various mortality risks according to the score are(28) 
Score Mortality risk 
0-2 6% 
3-5 24% 
>6 88% 
 
The drawbacks of these scoring systems are  
1. All are based on retrospective studies. 
2. All are from the east where the causative factors are different as compared to the rest of the world and 
India. 
3. None of the above scoring systems have a validation study. 
Hence there is a need for proper and simple scoring system which not only includes laboratory parameters 
but also clinical history and examination.  
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3.10.0. Treatment: 
Treatment depends on the type of infection: necrotising or non necrotising.  
3.10.1. Non necrotising soft tissue infection: 
In non necrotising soft tissue infection patient can be treated with oral or IV antibiotics based on the 
severity of infection.  Streptococcus and Staphylococcus needs to be covered and antibiotics of choice are 
Cephalosporin, Penicillin, Vancomycin or Clindamycin. Antibiotics need to be administered for 7-10 days 
(28).  
This needs to be supported with anti oedema measures like limb elevation, hygroscopic dressings, 
diuretics or compression stockings(29). Fasciotomy is recommended when anti oedema measures fail and 
compartment syndrome ensues. 
3.10.2. Necrotising soft tissue infection: 
a) Surgical therapy: 
Necrotising soft tissue infection is a surgical emergency and surgery is the mainstay of treatment in these 
patients. The aim of surgery is to perform aggressive debridement of all necrotic tissue until healthy, 
viable (bleeding) tissue is reached(30). Tissue samples are to be sent for Gram stain and culture. The 
wound needs re-evaluation after 24 hours and re-debridement is to be considered if unhealthy tissue is 
present. Once the wound is healthy and granulating they can be covered with skin graft or myocutaneous 
flaps. Multiple debridements may be needed for adequate control of infection(7). 
In severe infections amputation may be required for adequate source control. Amputation might be 
needed when there is severe necrosis of muscle groups rendering it not viable. Twenty percent of patients 
with NSTI might require amputation(2). 
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The relative risk of death was 7.5 percent higher in patients with NSTI who did not undergo surgical 
debridement and the risk was nine fold if the surgical treatment was delayed more than 24 hours(2). Early 
debridement had a mortality of 4 percent as compared to delayed debridement which had 38 percent 
mortality(31). 
b) Antibiotics in STI: 
Antibiotics therapy is an adjunct to surgical therapy in patients with NSTI’s. The role of antibiotic alone in 
NSTI is very limited as  thrombosis of vessels leads to inadequate supply to the tissues. Penicillin and 
Clindamycin are very effective in covering monomicrobial organisms. Recent emergence of MRSA is 
leading to wide spread use of second line antibiotics like Vancomycin, Linezolid, Daptomycin etc. 
Clindamycin is still effective as it inhibits the M protein of Group A Streptococci(2,9).  
Polymicrobial organisms especially with gram negative bacteria needs carbepenems like Meropenem, 
Imepenem etc. The antibiotic needs to be adjusted according to the tissue culture report once obtained. 
The duration of antibiotics is least studied upon. General consensus is to give therapy for 10 – 14 days(2). 
c) Immune therapy in STI: 
IV Immunoglobulin therapy is advocated in some trials but it is not FDA approved for necrotising soft 
tissue infections. This use of this agent is based on a theoretical assumptions  that it can bind 
staphylococcal- and streptococcal derived exotoxins, thereby limiting the systemic cytokine release which 
is associated with systemic inflammatory response syndrome(2). 
d) Adjuvant therapy in STI: 
Hyperbaric oxygen delivery is based on animal models which showed to inhibit infection of Clostridia. It 
also was found to augment the oxidative burst and killing ability of leukocytes and can enhance efficacy of 
antibiotics by increasing local oxygen tension in tissue(32–34). But its use in humans still remains 
controversial. 
30 
 
e) Secondary prevention in STI: 
Post exposure prophylaxis is advocated in patients with group A Streptococcus. Its aim is to prevent the 
secondary infection due to group A Streptococcus in people who are in close household contacts with type 
II soft tissue infections(35). 
3.11.0. Outcome and Factors predicting disease severity: 
The mortality with soft tissue infections especially in the necrotising group can be as high as 25-35 percent 
despite optimal therapy(3,7). The patients with toxic shock have a mortality of 28 percent(36). Most often 
the mortality is due to delay in initiating the appropriate treatment which is due to delay in diagnosis. The 
diagnosis was correct only in 38 percent of the patients at initial evaluation(2).  
There are various studies done to identify factors predicting the disease severity. All these studies were 
retrospective analysis of patients with necrotising soft tissue infections. The various parameters shown to 
predict severity are as follows  
Factors predicting mortality and morbidity in soft tissue 
infections  across various retrospective analysis 
Factors References 
Low haematocrit (8,24,28,37) 
High counts (8,24,28,37) 
Left shift of differential counts (28) 
Hypotension (systolic B.P <90 mm of hg) (3,8,37) 
Platelets , 100000/ cu mm (38) 
Coagulopathy (37) 
Hemorrhagic bullae (3,8) 
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Factors predicting mortality and morbidity in soft tissue 
infections  across various retrospective analysis 
Factors References 
High C- Reactive protein (24) 
Hyponatremia (24,28,38,39) 
High creatinine (24,28,37,38) 
Low Glasgow Coma Scale (8) 
Hypothermia (28) 
High lactate (39) 
Old age (28,37) 
Tachycardia (28) 
Heart disease (3) 
Liver disease (3) 
Malignancy (8) 
Diabetes mellitus (8,37) 
Aeromonas species in culture (3,8) 
Vibrio Species in culture (3,8) 
Fungal species in culture (3,8) 
Bacteraemia (3,40) 
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The drawbacks of all these studies were 
1. They were all retrospective studies. 
2. As they were all done on patients proven to have necrotising soft tissue infection and hence there may 
be bias which is to be excluded. 
3. As there was no regression analysis done on normal controls, these factors actually might not be the 
actual predictors of severity of the disease. 
Hence we propose this prospective nested case control study to predict the factors associated with 
mortality and morbidity in patients with soft tissue infections. 
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4. Methods and materials 
4.1.0. Design: 
After discussion with the statistician, a nested case control study was designed. 
Patients with no mortality and morbidity were grouped under one arm where as patients with mortality 
and morbidity was grouped under another arm. 
Definition of morbidity and mortality: 
In our study, morbidity was defined as any patients requiring 
1. Re-debridement 
2. Amputation 
3. Inotropic support 
4. Ventilator support 
5. Dialysis 
6. Post operative myocardial infarct 
In our study, mortality was considered as death that occurred in the hospital during the course of 
treatment for STI. 
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4.2.0. Sample size: 
Based on the study(3) the sample size was calculated to be 55 in each arm.  
n = 2PQ (Zα+Zβ)2 
          (PI-P0)
2 
 
 PI = P0(OR) 
      P0 (OR-1) +1 
 
 
 P = P0+PI 
            2 
 
 
  n - Sample size 
  Zα – Significance level – 1.96 
  Zβ – Power of the study – 0.84 
  OR – Odds Ratio – 3.5 
  P0 – Proportion with heart Disease among the control group 0.14 
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4.3.0. Recruitment: 
Institutional research board clearance was obtained before the start of the study. 
     
    Figure 1: Consort statement of the study  
All the patients admitted in the surgical wards with a diagnosis of soft tissue infections were included in 
the study. 
All patients were explained about the study after giving them the information sheet (Annexure 2). 
Informed consent (Annexure 3) was taken who were all willing to participate in the study. Those who did 
not give consent were not recruited in the study. 
After informed consent, the details required as per the proforma (Annexure 1) was collected. 
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They were all followed up during their stay in hospital and their progress was noted for any morbidity or 
mortality. 
Patients were recruited till the sample size was reached in either arm. 
There were total of 123 patients recruited. Of which 68 patients were in non mortality and morbidity arm. 
The study was conducted till the target sample size was reached in either arm. 
Out of 68 patients in non mortality and morbidity arm, random selection of 55 patients was done by 
computer software. 
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4.4.0. Analysis: 
Analysis was done in SPSS software version 18.0 (licensed by IBM) with the help of the statistician. 
The cohort provided the information on mortality, morbidity and 95% confidence interval. 
By using nested case control approach we estimated the magnitude of association between selected risk 
factors and mortality and morbidity. 
Simultaneous adjustment for confounders was done using unconditional logistic regression.  
All study variables were described using descriptive statistical methods. Continuous variables were 
summarised using mean with standard deviation.  
For skewed variables median with range were used. For categorical variables frequencies with 
percentages were used.  
The association between mortality/morbidity and other categorical parameters (hypotension, etc) were 
assessed using chi – square test.  
For continuous variables either t-test or corresponding non parametric test were used.  
Variables with a p < 0.05 were considered for the multivariable analysis. Logistic regression analysis were 
done to identify factors associated with mortality/morbidity. 
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5. Results 
5.1.0. Descriptive analysis:  
5.1.1. Age distribution: 
The age distribution was between 28 years to 87 years with a mean of 57 years and median of 58 years. 
The disease was predominantly affecting the age group of 40 – 60 years.  
Table 1: Distribution of age in patients with soft tissue infections 
Age N Minimum Maximum Mean Median Mode Std. 
deviation 
110 28 87 56.65 57.5 50 14.26 
 
 
Figure 2: Distribution of age in patients with soft tissue infections.  
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5.1.2. Gender distribution: 
There was a predilection for male population for this disease. 68.2 percent (75 out of 110) of the patients 
were male as compared to 31.8 percent (35 out of 110) who were female. 
   
Figure 3: Distribution of gender in patient with soft tissue infections 
 
5.1.3. Duration of presenting illness: 
The duration of presenting illness varied from 1 day to 45 days with a mean of 9 days and median of 7 
days. Most of the patients presented on the third day after the start of symptoms. 
Table 2: Duration of symptoms at presentation to hospital in patients with STI 
 
Duration of 
symptoms 
N Minimum Maximum Mean Median Mode Std. 
Deviation 
110 1 45 8.83 7 3 8.135 
 
  
Male 
68.2% 
Female 
31.8% 
42 
 
5.1.4. Mode of onset: 
Spontaneous mode of onset was the most common followed by trauma. 55.5 percent (61 out of 110) of 
patients had spontaneous onset but trauma was the cause in 40.9 percent (45 out of 110) of the patients. 
The other modes of onset included insect bites (0.9 percent) and surgery (2.7 percent). 
   
  Figure 4: Mode of onset of symptoms in patients with soft tissue infections 
 
5.1.5. Associated illnesses: 
69.1 percent (76 out of 110) of patients had associated illnesses at presentation. Diabetes mellitus was the 
most common associated illness which was seen in 56.4 percent (62 out of 110) of the patients. 
Hypertension was second most common illness seen in 31.8 percent (35 out of 110) of patients. Cardiac 
and chronic renal disease was seen in 10 percent and 7.3 percent of the patients respectively. The other 
illnesses associated were chronic liver disease (2.7 percent), vascular disorders (3.6 percent) and 
malignancy (1.8 percent). The patient with malignancy had undergone bilateral inguinal block dissection 
for carcinoma penis. 
  
55.5% 
40.9% 
2.7% 
0.9% 
Spontaneous Trauma Surgery Insect bite 
43 
 
   
   Figure 5: Distribution of associated illnesses in patients with STI 
 
5.1.6. Number of times operated: 
10.9 percent (12 out of 110) of patients underwent two operations where as 1.8 percent (2 out of 110) 
had undergone 3 operations for source control.                        
            
Figure 6: Number of times patients underwent operation for STI 
 
 
  
56.4% 
31.8% 
10% 
7.3% 
2.7% 1.8 3.6% 0.9% 
87.3% 
10.9% 
1.8% 
One time Two times Three times 
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5.1.7. Amputations: 
In our study 20 percent (22 out of 110) of the patients had undergone amputation as operation for source 
control. 18 out of 22 patients who underwent amputation survived where as only 4 out of 22 patients 
expired during their course of treatment.  
  Table 3: Mortality rate in patients who underwent amputation for STI 
 Mortality Total 
 No yes  
Amputation No 77 11 88 
Yes 18 4 22 
Total 95 15 110 
  
5.1.8. Inotropic requirements: 
Patients who required either preoperative or post operative inotropic support for hypotension comprised 
of 25.5 percent (28 out of 110). 
   
Figure 7: Patients with STI requiring Inotropes perioperatively  
  
Yes 
25.5% 
No 
74.5% 
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5.1.9. Ventilation: 
18.2 percent (20 out of 110) of patients required post operative ventilation in view of severe sepsis or 
acute respiratory distress syndrome. One patient required ventilator support due to pulmonary oedema 
caused by myocardial infarct. 
13 out of 20 patients who required ventilation postoperatively died due to the disease. 
  Table 4: Mortality in patients who had ventilation perioperatively 
 Mortality Total 
 No Yes  
Ventilation No 88 2 90 
Yes 7 13 20 
Total 95 15 110 
 
 
   
Figure 8: Patient with STI requiring ventilation perioperatively 
  
Yes 
18.2% 
No 
81.8% 
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5.1.10. Need for dialysis: 
7.3 percent (8 out of 110) of patients required dialysis due to acute renal failure or acute on chronic renal 
failure. 3 patients out of 8 who required dialysis were dialysis independent at the time of discharge. The 
other 5 patients succumbed to illness. 
 
Table 5: Mortality in patients who had dialysis for renal failure 
 Mortality Total 
 No Yes  
Dialysis No 92 10 102 
yes 3 5 8 
Total 95 15 110 
 
 
 
 
Figure 9: Patients with STI requiring Dialysis for renal failure 
  
Yes 7.3% 
No 92.7% 
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5.1.11. Myocardial infarct: 
5.5 percent (6 out of 110) of patient had myocardial infarct during the stay in hospital in the immediate 
post operative period. 4 out of 6 patient who had myocardial infarct expired. 
Table 6: Mortality in patients who had myocardial infarct 
 Mortality Total 
 No Yes  
Myocardial 
infarct 
No 93 11 104 
yes 2 4 6 
Total 95 15 110 
 
 
5.1.12. Mortality: 
We had total of 15 patients who succumbed to the disease, which comprised 14 percent of patients.  
   
Figure 10: Mortality in patients with STI  
  
Mortality 
14% 
Non mortality 
86% 
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5.1.13. Tissue cultures: 
Tissue for cultures was sent only for 71.8 percent (79 out of 110) of patients. Of these cultures were 
positive in 69 patients and sterile in 10 patients.  
In the culture positive group 62.3 percent (43 patients) had polymicrobial type I STI where as 37.6 percent 
(26 patients) had monomicrobial type II STI. 
There was no type III and type IV STI found in our study. 
8 out of 15 patients (53.3 percent of mortality) died of type II STI in contrast with type I STI where the 
mortality was 5 out of 15 (33.3 percent). 
5.1.14. Organisms in tissue culture: 
In type I STI, E. Coli was the most common organism (65.1 percent) followed by Enterococcus (37.2 
percent), NFGNB (27.9 percent) and pseudomonas (20.9 percent). The other organisms isolated were 
MRSA, MSSA, Klebsiella, Enterobacter, Proteus Spp, Morganella, Aeromonas Spp and Bacteroides. 
 
Figure 11: Organisms isolated in type I NSTI 
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Most common organism seen in the Type II infection is Group A Streptococci comprising of 42.3 percent 
(11 out of 26 patients) followed by Methicillin sensitive Staphylococcus aureus (MSSA) and Methicillin 
resistant Staphylococcus aureus (MRSA). The other organisms isolated were Klebsiella, E.coli, Non 
fermenting gram negative bacteria, Enterococcus. 
 
 
 
Figure 12:  Organisms isolated in Type II NSTI 
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5.2.0. Analysis of predictors of morbidity in STI 
5.2.1. Univariate analysis: 
The descriptive analysis (mean, Standard Deviation) of various variables predicting morbidity in STI is as 
follows 
 
Table 7: Descriptive analysis of variables predicting morbidity in STI 
Variables 
 
Outcome Number 
(n) 
 
Mean Standard 
deviation 
Odds ratio 
Age 
 
Non- 
Morbidity 
55 58.71 13.67 0.979 
Morbidity 
 
55 54.58 14.664 
Heart rate 
 
Non- 
Morbidity 
55 89.78 11.774 1.071 
Morbidity 
 
55 105.49 19.022 
Systolic blood 
pressure 
 
Non- 
Morbidity 
55 121.49 15.061 0.974 
Morbidity 
 
55 109.16 26.868 
Diastolic blood 
pressure 
 
Non- 
Morbidity 
55 72.47 11.674 0.983 
Morbidity 
 
55 68.55 18.051 
Respiratory rate 
 
Non- 
Morbidity 
55 19.49 4.799 1.139 
Morbidity 
 
55 23.45 6.928 
Glasgow coma 
scale 
 
 
 
Non- 
Morbidity 
55 15.00 0.000 0.000 
Morbidity 55 14.49 1.275 
Haemoglobin 
 
Non- 
Morbidity 
55 10.780 2.2390 0.970 
Morbidity 
 
55 10.618 2.4222 
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Variables 
 
Outcome Number 
(n) 
 
Mean Standard 
deviation 
Odds ratio 
Total counts 
 
Non- 
Morbidity 
55 16401.82 6755.012 1.000 
Morbidity 55 17601.82 8140.718 
Elevated 
neutrophils 
 
Non- 
Morbidity 
55 77.02 12.027 1.055 
Morbidity 
 
55 83.33 10.736 
Platelets 
 
Non- 
Morbidity 
55 262436.38 110892.461 1.000 
Morbidity 55 246272.73 136938.950 
Prothrombin time 
 
Non- 
Morbidity 
55 14.309 14.6855 0.997 
Morbidity 
 
55 13.962 3.3189 
INR 
 
Non- 
Morbidity 
55 1.293 1.2142 0.970 
Morbidity 55 
 
1.269 0.3150 
APTT Non- 
Morbidity 
55 36.171 20.5407 0.997 
Morbidity 55 
 
35.324 11.2615 
Urea 
 
Non- 
Morbidity 
55 43.85 25.551 1.022 
Morbidity 55 
 
71.49 49.654 
Creatinine 
 
Non- 
Morbidity 
55 1.631 0.9108 1.484 
Morbidity 55 2.304 1.8573 
Sodium 
 
Non- 
Morbidity 
55 132.96 4.046 0.841 
Morbidity 
 
55 129.11 5.560 
Potassium 
 
Non- 
Morbidity 
55 3.907 0.5405 1.284 
Morbidity 
 
55 4.053 0.9465 
Total bilirubin Non- 
Morbidity 
55 0.922 0.7208 2.258 
Morbidity 
 
55 1.665 1.6027 
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Variables 
 
Outcome Number 
(n) 
 
Mean Standard 
deviation 
Odds ratio 
Albumin 
 
Non- 
Morbidity 
55 2.900 0.6374 0.443 
Morbidity 
 
55 2.569 0.6455 
Glucose 
 
Non- 
Morbidity 
55 195.36 92.458 1.001 
Morbidity 
 
55 203.53 117.370 
Serum lactate Non- 
Morbidity 
55 2.045 1.1519 1.167 
Morbidity 
 
55 2.496 2.2371 
Base deficit Non- 
Morbidity 
55 3.931 2.7512 1.224 
Morbidity 
 
55 7.149 5.6079 
Serum myoglobin Non- 
Morbidity 
55 82.29 95.778 1.018 
Morbidity 
 
55 639.93 2311.128 
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5.2.2. Independent samples test for continuous variables: 
All the variables were analysed with independent samples test with assumption of null hypothesis.  
 
The variables found to be significant for prediction of morbidity using assumption of homogeneity of 
variance (Levine’s test for equality of variance) are  heart rate, systolic blood pressure, diastolic blood 
pressure, respiratory rate, Glasgow coma scale, total counts, urea, creatinine, potassium, total bilirubin, 
serum lactate, base deficit, myoglobin. 
 
This was further analysed by using Levine’s test for equality of means. This showed the following variables 
are the ones that actually violate the assumption of homogeneity. They are heart rate, systolic blood 
pressure, respiratory rate, Glasgow coma scale, neutrophils, urea, creatinine, sodium, total bilirubin, 
albumin and base deficit.   
 
The following variables like diastolic blood pressure, total counts, potassium, serum lactate and serum 
myoglobin though found to be significant by Levine’s test for equality of variance were not found to be 
significant by Levine’s test for equality of means.  
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Table 8: Analysis of variables by independent samples test predicting morbidity in STI 
Variables Variance 
assumption 
Significance by 
Levine’s test for 
quality of 
variance 
Significance by 
Levine’s test for 
quality of 
means 
95% Confidence 
interval 
Lower Upper 
Age Equal variance 
assumed 
0.616 0.13 -1.231 9.485 
Equal variance 
not assumed 
 0.13 -1.231 9.486 
Heart rate 
 
Equal variance 
assumed 
0.001 0 -1.231 -9.73 
Equal variance 
not assumed 
 0 -1.231 -9.716 
Systolic blood 
pressure 
Equal variance 
assumed 
0.001 0.004 4.095 20.56 
Equal variance 
not assumed 
 0.004 4.069 20.585 
Diastolic blood 
pressure 
Equal variance 
assumed 
0.016 0.178 -1.818 9.673 
Equal variance 
not assumed 
 0.179 -1.829 9.684 
Respiratory rate 
 
Equal variance 
assumed 
0.03 0.001 -6.216 -1.711 
Equal variance 
not assumed 
 0.001 -6.219 -1.708 
Glasgow coma 
scale 
Equal variance 
assumed 
0 0.004 0.168 0.85 
Equal variance 
not assumed 
 0.005 .164 0.854 
Haemoglobin Equal variance 
assumed 
0.687 0.717 -0.7198 1.0434 
Equal variance 
not assumed 
 0.717 -0.7199 1.0435 
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Variables Variance 
assumption 
Significance by 
Levine’s test for 
quality of 
variance 
Significance by 
Levine’s test for 
quality of 
means 
95% Confidence 
interval 
Lower Upper 
Total counts Equal variance 
assumed 
0.028 0.402 -4027.34 1627.341 
Equal variance 
not assumed 
 0.402 -4028.43 1628.431 
Elevated 
neutrophils 
 
Equal variance 
assumed 
0.329 0.004 -10.618 -2 
Equal variance 
not assumed 
 0.005 -10.619 -2 
Platelets 
 
Equal variance 
assumed 
0.284 0.498 -30932.7 63259.98 
Equal variance 
not assumed 
 0.498 -30955.7 63283.05 
Prothrombin 
time 
 
Equal variance 
assumed 
0.252 0.864 -3.6768 4.3713 
Equal variance 
not assumed 
 0.865 -3.7143 4.4088 
INR 
 
Equal variance 
assumed 
0.286 0.889 -0.3116 0.3589 
Equal variance 
not assumed 
 0.889 -0.3146 0.3618 
APTT 
 
Equal variance 
assumed 
0.978 0.789 -5.4137 7.1083 
Equal variance 
not assumed 
 0.789 -5.4343 7.1289 
Urea 
 
Equal variance 
assumed 
0.003 0 -42.562 -12.711 
Equal variance 
not assumed 
 0 -42.619 -12.654 
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Variables Variance 
assumption 
Significance by 
Levine’s test for 
quality of 
variance 
Significance by 
Levine’s test for 
quality of 
means 
95% Confidence 
interval 
Lower Upper 
Creatinine Equal variance 
assumed 
0.007 0.018 -1.2256 -0.1198 
Equal variance 
not assumed 
 0.018 -1.228 -0.1175 
Sodium 
 
Equal variance 
assumed 
0.053 0 2.017 5.692 
Equal variance 
not assumed 
 0 2.015 5.694 
Potassium 
 
Equal variance 
assumed 
0 0.325 -0.4368 0.1459 
Equal variance 
not assumed 
 0.325 -0.4376 0.1467 
Total bilirubin Equal variance 
assumed 
0.002 0.002 -1.2133 -0.274 
Equal variance 
not assumed 
 0.002 -1.2157 -0.2716 
Albumin Equal variance 
assumed 
0.703 0.008 0.0885 0.5734 
Equal variance 
not assumed 
 0.008 0.0884 0.5734 
Glucose Equal variance 
assumed 
0.084 0.686 -48.098 31.771 
Equal variance 
not assumed 
 0.686 -48.123 31.796 
Serum lactate Equal variance 
assumed 
0.024 0.187 -1.1234 0.2216 
Equal variance 
not assumed 
 0.188 -1.126 0.2242 
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Variables Variance 
assumption 
Significance by 
Levine’s test for 
quality of 
variance 
Significance by 
Levine’s test for 
quality of 
means 
95% Confidence 
interval 
Lower Upper 
Base deficit Equal variance 
assumed 
0.001 0 -4.8877 -1.5487 
Equal variance 
not assumed 
 0 -4.8948 -1.5416 
Serum 
myoglobin 
Equal variance 
assumed 
0.012 0.077 -1175.88 60.603 
Equal variance 
not assumed 
 0.079 -1182.91 67.636 
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5.2.3. Cross tabs for categorical data: 
The following variables were found to be significant predictors for morbidity using Pearson’s chi square 
and Fischer’s exact test.  
 
5.2.4. Fever: 
Fever as a presenting symptom was found to be a significant variable with a Pearson’s chi square value of 
0.00 with a risk estimate of 5.701. 
  Table 9: Analysis of fever as a variable predicting morbidity in STI     
 Non morbidity vs. 
Morbidity 
Total 
Non 
morbidity 
Morbidity 
FEVER No Count 29 9 38 
% within FEVER 76.3% 23.7% 100% 
yes Count 26 46 72 
% within FEVER 36.1% 63.9% 100% 
Total 
 
Count 55 55 110 
 
 
 Value df Asymp sig (2 
sided) 
Exact Sig (2 
sided) 
P-value 
OR 95% CI 
Lower Upper 
Pearson chi 
square 
16.082 1 0.000  5.70 2.34 13.87 
Fischer exact test   0.000 
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5.2.5. Haemorrhagic bullae: 
Haemorrhagic bulla was found to be significant variable with a Fischer’s exact test value of 0.000. 
 
 Table 10: Analysis of haemorrhagic bullae as a variable predicting morbidity in STI 
Haemorrhagic 
bullae 
Non morbidity vs. Morbidity Total 
 
 
Non 
morbidity 
Morbidity 
no Count 54 41 95 
 % within 
Bullae 
56.8% 43.2% 100.0% 
yes Count 1 14 15 
 % within 
Bullae 
6.7% 93.3% 100.0% 
Total Count 
 
55 55 110 
 
 
 
 Value df Asymp sig (2 
sided) 
Exact Sig (2 
sided) 
OR 95% CI 
Lower Upper 
Pearson chi 
square 
13.046 1 0.000  18.44 2.32 145.97 
Fischer exact test   0.000 
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5.2.6. Left shift in differential count: 
Left shift in the differential counts were found to be significant variable with a Pearson chi square value of 
0.057 and an odds ratio of 2.571. 
 
  Table 11: Analysis of left shift in differential count as a variable predicting morbidity in STI 
Left shift in 
differential count 
Non morbidity vs. Morbidity Total 
 
 
Non 
morbidity 
Morbidity 
no Count 48 40 88 
 % within left 
shift 
54.5% 45.5% 100.0% 
yes Count 7 15 22 
 % within left 
shift 
31.8% 68.2% 100.0% 
Total Count 
 
55 55 110 
 
 
 
 Value df Asymp sig (2 
sided) 
Exact Sig (2 
sided) 
OR 95% CI 
Lower Upper 
Pearson chi 
square 
3.636 1 0.057  2.57 0.95 6.92 
Fischer exact test   0.094 
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5.2.7. Number of re-operations: 
Patients undergoing multiple operations (more than once) were found to have significant morbidity with a 
Pearson’s chi square value of 0.00. 
 
Table 12; Analysis of multiple operations as a variable predicting morbidity in STI 
Number of times 
operated 
Non morbidity vs. Morbidity Total 
 
 
Non 
morbidity 
Morbidity 
0 Count 55 41 96 
 % with in 
multiple 
operations 
57.3% 42.7% 100.0% 
1 Count 0 12 12 
 % with in 
multiple 
operations 
0% 100% 100.0% 
2 Count 0 2 2 
 % with in 
multiple 
operations 
0% 100% 100% 
Total Count 
 
55 55 110 
 
 
 Value df Asymp sig (2 
sided) 
Exact Sig (2 
sided) 
OR 95% CI 
Lower Upper 
Pearson chi 
square 
16.042 2 0.000  NA NA NA 
Fischer exact test   NA 
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5.2.8. Amputation: 
Amputation for patients with STI was found to be a significant variable predicting morbidity in STI with a 
Fischer exact test value of 0.000. 
 
Table 13: Analysis of amputation as a variable predicting morbidity in STI 
Amputation Non morbidity vs. Morbidity Total 
 
 
Non 
morbidity 
Morbidity 
no Count 55 33 88 
 % within 
amputation 
62.5% 37.5% 100.0% 
yes Count 0 22 22 
 % within 
amputation 
0% 100% 100.0% 
Total Count 
 
55 55 110 
 
 
 
 Value df Asymp sig (2 
sided) 
Exact Sig (2 
sided) 
OR 95% CI 
Lower Upper 
Pearson chi 
square 
27.5 1 0.000  0.38 0.286 0.491 
Fischer exact test   0.000 
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5.2.9. Ventilator support: 
Ventilator support for patients with STI was found to be a significant predictor of morbidity with Fischer 
exact value of 0.000. 
 
Table 14: Analysis of ventilation as a variable predicting morbidity in STI 
Ventilation Non morbidity vs. Morbidity Total 
 
 
Non 
morbidity 
Morbidity 
no Count 55 35 90 
 % within 
ventilation 
61.1% 38.9% 100.0% 
yes Count 0 20 20 
 % within 
ventilation 
0% 100% 100.0% 
Total Count 
 
55 55 110 
 
 
 
 Value df Asymp sig (2 
sided) 
Exact Sig (2 
sided) 
OR 95% CI 
Lower Upper 
Pearson chi 
square 
24.4 1 0.000  0.39 0.300 0.504 
 
Fischer exact test   0.000 
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5.2.10. Inotropes requirement: 
Inotropic support for patients with STI was found to be a significant predictor of morbidity with Fischer 
exact value of 0.000. 
 
Table 15: Analysis of inotropes as a variable predicting morbidity in STI 
Inotropes Non morbidity vs. Morbidity Total 
 
 
Non 
morbidity 
Morbidity 
no Count 55 27 82 
 % within 
inotropes 
67.1% 32.9% 100.0% 
yes Count 0 28 28 
 % within 
inotropes 
0% 100% 100.0% 
Total Count 
 
55 55 110 
 
 
 
 Value df Asymp sig (2 
sided) 
Exact Sig (2 
sided) 
OR 95% CI 
Lower Upper 
Pearson chi 
square 
37.561 1 0.000  0.33 0.242 0.448 
 
Fischer exact test   0.000 
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5.2.11. Dialysis requirement: 
Dialysis for patients with STI was found to be a significant predictor of morbidity with Fischer exact value 
of 0.006. 
 
Table 16: Analysis of dialysis as a variable predicting morbidity in STI 
Dialysis Non morbidity vs. Morbidity Total 
 
 
Non 
morbidity 
Morbidity 
no Count 55 47 102 
 % within 
dialysis 
53.9% 46.1% 100.0% 
yes Count 0 8 8 
 % within 
dialysis 
0% 100% 100.0% 
Total Count 
 
55 55 110 
 
 
 
 Value df Asymp sig (2 
sided) 
Exact Sig (2 
sided) 
OR 95% CI 
Lower Upper 
Pearson chi 
square 
8.627 1 0.003  0.46 0.374 0.568 
Fischer exact test   0.006 
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5.2.12. Myocardial infarct: 
Myocardial infarct during the hospital course for patients with STI was found to be a significant predictor 
of morbidity with Fischer exact value of 0.027. 
 
Table 17: Analysis of myocardial infarct as a variable predicting morbidity in STI 
Myocardial 
infarct 
Non morbidity vs. Morbidity Total 
 
 
Non 
morbidity 
Morbidity 
no Count 55 49 104 
 % within 
myocardial 
infarct 
52.9% 47.1% 100.0% 
yes Count 0 6 6 
 % within 
myocardial 
infarct 
0% 100% 100.0% 
Total Count 
 
55 55 110 
 
 
 
 Value df Asymp sig (2 
sided) 
Exact Sig (2 
sided) 
OR 95% CI 
Lower Upper 
Pearson chi 
square 
6.346 1 0.012  0.47 0.384 0.578 
Fischer exact test   0.027 
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5.2.13. Positive tissue culture: 
Positive tissue culture for patients with STI was found to be a significant predictor of morbidity with 
Fischer exact value of 0.001. 
 
Table 18: Analysis of positive tissue culture as a variable predicting morbidity in STI 
Tissue culture Non morbidity vs. Morbidity Total 
 
 
Non 
morbidity 
Morbidity 
no Count 24 7 31 
 % within 
tissue culture 
77.4% 22.6% 100.0% 
yes Count 31 48 79 
 % within 
tissue culture 
39.2% 60.8% 100.0% 
Total Count 
 
55 55 110 
 
 
 
 Value df Asymp sig (2 
sided) 
Exact Sig (2 
sided) 
OR 95% CI 
Lower Upper 
Pearson chi 
square 
12.981 1 0.000  5.31 2.042 13.801 
Fischer exact test   0.001 
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5.2.14. Other non significant variables: 
The other variables analysed like sex, type of onset, diabetes mellitus, hypertension, cardiac co-
morbidities, renal disease, liver disease, steroid usage, vascular disease, malignancy or absence of 
peripheral pulses were not found to be significant.  
Table 19: Analysis of variables not significant in predicting morbidity in STI  
Variables OR 
 
P value 95% CI 
Lower Upper 
Sex 0.464 0.065 0.204 1.058 
Type of onset NA 0.216 NA NA 
Co morbidities 1.186 0.680 0.528 2.665 
Diabetes mellitus 0.863 0.701 0.406 1.834 
Hypertension 0.777 0.539 0.348 1.738 
Cardiac co-morbidity 1.859 0.340 0.512 6.756 
Renal disease 0.577 0.463 0.131 2.542 
Liver disease 2.038 0.558 0.179 23.151 
Steroid usage 1.000 1.00 0.061 16.401 
Vascular disease 0.481 0.118 0.395 0.586 
Malignancy 0.496 1.000 0.410 0.599 
Absence of pulses 0.626 0.580 0.207 1.896 
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5.2.15. Multivariate analysis: 
The variables which were found to be significant by independent samples test, bivariate analysis and 
logistic regression were analysed by multivariate analysis. 
 
Table 20:  Multivariate analysis of significant variables predicting morbidity in STI 
Variables Odds ratio 
 
95% CI P value 
Lower Upper 
Heart rate 1.037 
 
0.989 1.088 0.136 
Blood pressure 0.989 
 
0.959 1.020 0.484 
GCS 0.000 
 
0.000 - 0.997 
Respiratory rate 0.949 
 
0.826 1.090 0.459 
Elevated neutrophils 1.063 
 
0.993 1.139 0.079 
Urea 1.017 
 
0.990 1.045 0.217 
Creatinine 0.734 
 
0.358 1.508 0.400 
Sodium  0.838 0.735 0.955 0.008 
Albumin 1.012 
 
0.351 2.913 0.983 
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Variables Odds ratio 
 
95% CI P value 
Lower Upper 
Total bilirubin 1.458 
 
0.832 2.554 0.187 
 
 
Base deficit 1.033 
 
0.882 1.210 0.686 
Fever 4.300 
 
1.161 15.920 0.029 
Haemorrhagic bullae 12.373 0.570 268.497 0.109 
 
After multivariate analysis it was concluded that the following variables predict morbidity in soft tissue 
infections. 
The variables were  
1. Neutrophilia in differential count with a p value of 0.079. 
2. Low sodium at presentation with a p value of 0.008. 
3. Elevated temperature at presentation with a p value of 0.029. 
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5.3.0. Analysis of predictors of mortality in STI 
5.3.1. Univariate analysis: 
The descriptive analysis (mean, Standard Deviation) of various variables predicting mortality in STI is as 
follows. 
 
Table 21: Descriptive analysis of variables predicting mortality in STI 
Variables Outcome Number (n) Mean Standard 
deviation 
Age Non –mortality 95 57.34 14.589 
Mortality 
 
15 52.27 11.436 
Heart rate Non- Mortality 95 96.63 16.471 
Mortality 
 
15 104.00 23.312 
Systolic blood 
pressure 
Non- Mortality 95 117.64 20.624 
Mortality 
 
15 100.67 28.900 
Diastolic blood 
pressure 
Non- Mortality 95 71.64 14.199 
Mortality 
 
15 63.33 19.881 
Respiratory rate Non- Mortality 95 20.72 5.158 
Mortality 
 
15 26.27 9.881 
Glasgow coma scale 
 
 
Non- Mortality 95 14.85 0.785 
Mortality 
 
15 14.07 1.438 
Haemoglobin Non- Mortality 95 10.646 2.347 
Mortality 
 
15 11.033 2.209 
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Variables Outcome Number (n) Mean Standard 
deviation 
Total counts Non- Mortality 95 17426.32 7241.32 
Mortality 
 
15 14313.33 8567.78 
Neutrophils Non- Mortality 95 80.35 11.54 
Mortality 
 
15 79.07 13.625 
Platelets Non- Mortality 95 260326.33 121289.912 
Mortality 
 
15 216533.33 140446.16 
Prothrombin time Non- Mortality 95 13.895 11.193 
Mortality 
 
15 15.660 5.514 
INR Non- Mortality 95 1.258 0.928 
Mortality 
 
15 1.427 0.516 
APTT Non- Mortality 95 34.52 16.13 
Mortality 
 
15 43.49 17.23 
Urea Non- Mortality 95 54.44 38.39 
Mortality 
 
15 78.13 55.76 
Creatinine Non- Mortality 95 1.84 1.39 
Mortality 
 
15 2.773 1.86 
Sodium Non- Mortality 95 131.24 5.012 
Mortality 
 
15 129.73 6.386 
Potassium Non- Mortality 95 3.941 0.704 
Mortality 
 
15 4.227 1.105 
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Variables Outcome Number (n) Mean Standard 
deviation 
Total bilirubin Non- Mortality 95 1.107 0.877 
Mortality 
 
15 2.473 2.47 
Albumin 
 
Non- Mortality 95 2.789 0.643 
Mortality 
 
15 2.387 0.6871 
Glucose 
 
Non- Mortality 95 200.75 97.04 
Mortality 
 
15 191.20 151.41 
Serum lactate Non- Mortality 95 1.985 1.13 
Mortality 
 
15 4.080 3.491 
Base deficit Non- Mortality 95 4.471 3.155 
Mortality 
 
15 12.313 6.859 
Serum myoglobin Non- Mortality 95 148.38 221.106 
Mortality 
 
15 1708 4320.674 
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5.3.2. Independent samples test for continuous variable 
All the variables were analysed with independent samples test with assumption of null hypothesis.  
The variables found to be significant for prediction of mortality are systolic blood pressure, diastolic blood 
pressure, respiratory rate, GCS, urea, creatinine, total bilirubin, albumin, serum lactate and base deficit. 
Table 22: Analysis of variables predicting mortality by independent samples test 
Variables Odds ratio P Value 95% confidence interval 
Lower Upper 
Age 0.975 0.203 0.938 1.014 
Heart rate 1.022 0.139 0.993 1.052 
Systolic B.P 0.967 0.009 0.942 0.992 
Diastolic B.P 0.967 0.058 0.935 1.001 
Respiratory rate 1.121 0.004 1.036 1.213 
GCS 0.564 0.011 0.363 0.878 
Haemoglobin 1.078 0.548 0.845 1.375 
Total counts 1.000 0.138 1.000 1.000 
Neutrophils 0.991 0.695 0.949 1.036 
Platelets 1.000 0.206 1.000 1.000 
Prothrombin time 1.011 0.567 0.973 1.051 
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Variables Odds ratio P Value 95% confidence interval 
Lower Upper 
INR 1.162 0.516 0.739 1.829 
APTT 1.022 0.133 0.994 1.050 
Urea 1.011 0.052 1.000 1.022 
Creatinine 1.349 0.043 1.010 1.801 
Sodium 0.948 0.299 0.858 1.048 
Potassium 1.587 0.185 0.802 3.140 
Total bilirubin 1.809 0.005 1.200 2.727 
Albumin 0.399 0.033 0.172 0.927 
Glucose 0.999 0.743 0.994 1.005 
Serum lactate 1.730 0.002 1.214 2.465 
Base deficit 1.521 0.000 1.240 1.867 
Serum myoglobin 1.002 0.078 1.000 1.004 
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5.3.3. Cross tabs for categorical data: 
The following variables were found to be significant predictors for morbidity using Pearson’s chi square 
and Fischer’s exact test. 
5.3.4. Diabetes mellitus: 
Diabetes mellitus in patients with STI was found to be a significant variable predicting mortality with a 
significant p value of 0.013. 
 
Table 23: Analysis of Diabetes mellitus as a variable predicting mortality in STI 
Diabetes mellitus Non mortality vs. Mortality Total 
 
 
Non 
Mortality 
Mortality 
no Count 37 11 48 
 % within DM 77.1% 22.9% 100.0% 
yes Count 58 4 62 
 % within DM 93.5% 6.5% 100% 
Total Count 
 
95 15 110 
 
 
 Value df Asymp sig (2 
sided) 
Exact Sig (2 
sided) 
OR 95% CI 
Lower Upper 
Pearson chi 
square 
6.228 1 0.013  0.23 0.069 0.783 
Fischer exact test   0.023 
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5.3.5. Chronic Liver Disease: 
Chronic liver disease in patients with STI was found to be a significant variable predicting mortality with a 
Pearson chi square of 0.007 and Fischer’s exact test value of 0.048. 
 
Table 24: Analysis of Chronic liver disease as a variable predicting mortality in STI 
Chronic liver 
disease (CLD) 
Non mortality vs. Mortality Total 
 
 
Non 
Mortality 
Mortality 
no Count 94 13 107 
 % within CLD 87.9% 12.1% 100% 
yes Count 1 2 3 
 % within CLD 33.3% 66.7% 100% 
Total Count 
 
95 15 110 
 
 
 
 Value df Asymp sig (2 
sided) 
Exact Sig (2 
sided) 
OR 95% CI 
Lower Upper 
Pearson chi 
square 
7.365 1 0.007  14.46 1.224 170.89 
Fischer exact test   0.048 
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5.3.6. Fever: 
Fever as a presenting symptom in patients with STI was found to be nearly a significant variable predicting 
mortality with a Pearson chi square value of 0.063 and Fischer’s exact value of 0.082. 
 
Table 25: Analysis of fever as a variable predicting mortality in STI 
Fever Non mortality vs. Mortality Total 
 
 
Non 
Mortality 
Mortality 
no Count 36 2 38 
 % within fever 94.7% 5.3% 100% 
yes Count 59 13 72 
 % within fever 81.9% 18.1% 100% 
Total Count 
 
95 15 110 
 
 
 
 Value df Asymp sig (2 
sided) 
Exact Sig (2 
sided) 
OR 95% CI 
Lower Upper 
Pearson chi 
square 
3.456 1 0.063  3.966 0.846 18.59 
Fischer exact test   0.082 
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5.3.7. Haemorrhagic Bullae: 
Haemorrhagic bullae  as a presenting symptom in STI was found to be a significant variable predicting 
mortality with a Pearson chi square value of 0.000 and Fischer’s exact value of 0.001. 
 
Table 26: Analysis of haemorrhagic bullae as a variable predicting mortality in STI 
Haemorrhagic 
bullae 
Non mortality vs. Mortality Total 
 
 
Non 
Mortality 
Mortality 
no Count 87 8 95 
 % within 
bullae 
91.6% 8.4% 100% 
yes Count 59 13 72 
 % within 
bullae 
53.3% 46.7% 100% 
Total Count 
 
95 15 110 
 
 
 
 Value df Asymp sig (2 
sided) 
Exact Sig (2 
sided) 
OR 95% CI 
Lower Upper 
Pearson chi 
square 
16.090 1 0.000  9.516 2.736 33.09 
Fischer exact test   0.001 
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5.3.8. Left shift in differential count: 
Left shift in differential count was found to be a significant variable predicting mortality in patients with 
STI with a Pearson chi square value of 0.005 and Fischer’s exact value of 0.011. 
 
Table 27: Analysis of left shift as a variable predicting mortality in STI 
Left shift Non mortality vs. Mortality Total 
 
 
Non 
Mortality 
Mortality 
no Count 80 8 88 
 % within left 
shift 
90.9% 9.1% 100% 
yes Count 59 13 72 
 % within left 
shift 
68.2% 31.8% 100% 
Total Count 
 
95 15 110 
 
 
 
 Value df Asymp sig (2 
sided) 
Exact Sig (2 
sided) 
OR 95% CI 
Lower Upper 
Pearson chi 
square 
7.719 1 0.005  4.667 1.471 14.81 
Fischer exact test   0.011 
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5.3.9. Ventilation: 
Ventilation in patient with STI was found to be a significant variable predicting mortality with a Pearson 
chi square value of 0.000 and Fischer’s exact value of 0.000. 
 
Table 28: Analysis of ventilation as a variable predicting mortality in STI 
Ventilation Non mortality vs. Mortality Total 
 
 
Non 
Mortality 
Mortality 
no Count 88 2 90 
 % within 
ventilation 
97.8% 2.2% 100% 
yes Count 7 13 20 
 % within 
ventilation 
35.0% 65.0% 100% 
Total Count 
 
95 15 110 
 
 
 
 Value df Asymp sig (2 
sided) 
Exact Sig (2 
sided) 
OR 95% CI 
Lower Upper 
Pearson chi 
square 
54.76 1 0.000  81.714 15.292 436.65 
Fischer exact test   0.000 
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5.3.10. Inotropes: 
Inotropes in patient with STI was found to be a significant variable predicting mortality with a Pearson chi 
square value of 0.000 and Fischer’s exact value of 0.000. 
 
Table 29: Analysis of inotropes as a variable predicting mortality in STI 
Inotropes Non mortality vs. Mortality Total 
 
 
Non 
Mortality 
Mortality 
no Count 79 3 82 
 % within 
inotropes 
96.3% 3.7% 100% 
yes Count 16 12 28 
 % within 
inotropes 
57.1% 42.9% 100% 
Total Count 
 
95 15 110 
 
 
 
 Value df Asymp sig (2 
sided) 
Exact Sig (2 
sided) 
OR 95% CI 
Lower Upper 
Pearson chi 
square 
27.33 1 0.000  19.75 4.996 78.076 
Fischer exact test   0.000 
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5.3.11. Dialysis: 
Dialysis in patient with STI was found to be a significant variable predicting mortality with a Pearson chi 
square value of 0.000 and Fischer’s exact value of 0.001. 
 
Table 30: Analysis of dialysis as a variable predicting mortality in STI 
Dialysis Non mortality vs. Mortality Total 
 
 
Non 
Mortality 
Mortality 
no Count 92 10 102 
 % within 
dialysis 
90.2% 9.8% 100% 
yes Count 3 5 8 
 % within 
dialysis 
37.5% 62.5% 100% 
Total Count 
 
95 15 110 
 
 
 
 Value df Asymp sig (2 
sided) 
Exact Sig (2 
sided) 
OR 95% CI 
Lower Upper 
Pearson chi 
square 
17.49 1 0.000  15.33 3.180 73.93 
Fischer exact test   0.001 
 
  
84 
 
5.3.12. Other non significant variables: 
The other variables analysed like sex, type of onset, hypertension, cardiac co-morbidities, renal disease, 
steroid usage, vascular disease, malignancy, repeated operations and amputation were not found to be 
significant.  
Table 31: Analysis of variables not significant in predicting mortality in STI  
Variables OR 
 
P value 95% CI 
Lower Upper 
Sex 0.751 0.645 0.221 2.548 
Type of onset NA 0.476 NA NA 
Co-morbidities 0.454 0.155 0.150 1.374 
Hypertension 0.492 0.380 0.130 1.870 
Cardiac co-morbidity 1.470 0.644 0.285 7.574 
Renal disease 0.898 1.000 0.103 7.863 
Steroid usage 0.861 1.000 0.798 0.929 
Vascular disease 2.190 0.449 0.213 22.558 
Malignancy 0.682 1.000 0.800 0.930 
Repeated operations NA 0.713 NA NA 
Amputation 1.556 0.495 0.444 5.452 
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5.3.13. Multivariate analysis: 
The variables which were found to be significant by independent samples test, bivariate analysis and 
logistic regression were analysed by multivariate analysis. 
Table 32: Multivariate analysis of significant variables predicting mortality in STI 
Variables Odds ratio 
 
95% CI P value 
Lower Upper 
Diabetes mellitus 0.065 
 
0.007 0.573 0.014 
Ventilator support 
 
0.009 0.001 0.074 0.000 
Dialysis 
 
0.053 0.004 0.701 0.026 
 
After multivariate analysis it was concluded that the following variables predict mortality in soft tissue 
infections. 
The variables were  
1. Diabetes mellitus as a co morbid illness with a p value of 0.014. 
2. Requirement of ventilator support with a p value of 0.000. 
3. Requirement of dialysis with a p value of 0.026. 
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6. Discussion  
In the study done in our institution to find factors predicting mortality and morbidity, we found the 
following results. 
Soft tissue infections have a male predilection with 68.2 percent (75 out of 110) of population being male 
which is in comparison with the international population which is 67.2 % (8). 
The mean age of population having this problem was 57 years which is in comparison with international 
population which range from 48 years to 56 years (24)(12). 
Duration of presenting symptoms vary from 1 day to 45 days with a mean of 9 days and median of 7 days 
where as in other study it was 3.4 days (12). 
The mode of onset is predominantly spontaneous comprising of 55.5% of the population followed by 
trauma comprising of 40.9%. Surgery and insect bite comprised the remaining population. Whereas in the 
Western literature, trauma (38.3%) and spontaneous (31.2%) causes were the most common mode of 
onset (8). 
69.1 percent (76 out of 110) of patients had associated illnesses at presentation. Diabetes mellitus was the 
most common associated illness which was seen in 56.4 percent (62 out of 110) of the patients where as 
in literature it is 58.6%  - 70.8% (7,8). 
 Hypertension was second most common illness seen in 31.8 percent (35 out of 110) of patients. Cardiac 
and chronic renal disease was seen in 10 percent and 7.3 percent of the patients respectively. The other 
illnesses associated were chronic liver disease (2.7 percent), vascular disorders (3.6 percent) and 
malignancy (1.8 percent)(2,9,10). 
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There were 15 (15/110) mortalities in our study comprising of 13.6% of the total population where as in 
western literature it ranges form 25-35% (3,4,7). 
22% of the patients had undergone amputation in our study. 18.18% of population who had undergone 
amputation had expired where as 81.82% of the population who had amputation survived.  Of all the 
patients who had died, 73.33 did not have an amputation. 
25.5 percent (28 out of 110) of the patients required inotropic requirement perioperatively whereas it is 
25% in literature (8). 
18.2 percent (20 out of 110) of patients required post operative ventilation. Of all the patients who had 
died, 86.66% of the population required ventilation. 
7.3 percent (8 out of 110) of patients required dialysis due to acute renal failure or acute on chronic renal 
failure. 33.33& of patients who had died required dialysis. 
5.5 percent (6 out of 110) of patient had myocardial infarct during the stay in hospital in the immediate 
post operative period. 4 out of 6 patient who had myocardial infarct expired. 
Tissue for cultures was sent only for 71.8 percent (79 out of 110) of patients. Of these cultures were 
positive in 69 patients and sterile in 10 patients.  
In the culture positive group, 62.3 percent (43 patients) had polymicrobial type I STI where as 37.6 percent 
(26 patients) had monomicrobial type II STI. The most common type of infection in the literature was Type 
I STI which comprises of 55-75% of cases (3,7,9). 
 8 out of 15 patients (53.3 percent of mortality) died of type II (monomicrobial)STI in contrast with type I 
(polymicrobial) STI where the mortality was 5 out of 15 (33.3 percent). There were no Type III or type IV 
infections noted in our study. 
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In type I STI, Escherichia Coli was the most common organism (65.1 percent) followed by Enterococcus 
(37.2 percent), NFGNB (27.9 percent) and pseudomonas (20.9 percent). These organisms were the 
common isolates in type I soft tissue infections (3,7,10,28). 
Most common organism seen in the Type II infection is Group A Streptococci comprising of 42.3 percent 
(11 out of 26 patients) followed by Methicillin sensitive Staphylococcus aureus (MSSA) and Methicillin 
resistant Staphylococcus aureus (MRSA) which is same as in literature where Group A Streptococci is the 
most common comprising of 30% followed by Staphylococcus infection (3,10,14). 
Heart rate, systolic blood pressure, respiratory rate, Glasgow coma scale, neutrophils, urea, creatinine, 
sodium, total bilirubin, albumin and base deficit, fever, haemorrhagic bullae, left shift in differential 
counts, number of re operations, amputation,  ventilation, inotropic support, dialysis, positive tissue 
culture were found to be  significant variables by logistic regression analysis in predicting morbidity in 
patients with soft tissue infections. 
These are the variables that were identified as predictors of morbidity and mortality in soft tissue  
infection in various studies with varying significance (3,8,24,28,29,37–40). 
However multivariate analysis in our study revealed the following variables to be significant in predicting 
morbidity in soft tissue infections. The variables are  
1. Neutrophilia in differential count with a p value of 0.079. 
2. Low sodium at presentation with a p value of 0.008. 
3. Elevated temperature at presentation with a p value of 0.029. 
These above variables were found to predict morbidity in soft tissue infection in literature (24,28,38,39). 
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Similarly systolic blood pressure, diastolic blood pressure, respiratory rate, GCS, urea, creatinine, total 
bilirubin, albumin, serum lactate, base deficit, diabetes mellitus, chronic liver disease, fever, haemorrhagic 
bullae, left shift in differential counts, ventilation, inotropic support and dialysis were found to be 
significant variables by logistic regression analysis in predicting mortality in patients with soft tissue 
infections. 
However multivariate analysis in our study revealed the following variables to be significant in predicting 
mortality in soft tissue infections. The variables are  
1. Diabetes mellitus as a co morbid illness with a p value of 0.014. 
2. Requirement of ventilator support with a p value of 0.000. 
3. Requirement of dialysis with a p value of 0.026. 
The variables that predict mortality in soft tissue infections according to literature are tachycardia, 
hypothermia, elevated serum creatinine, age more than 50 years, elevated haematocrit, left shift in 
differential count, hypotension, malignancy, haemorrhagic bullae, Aeromonas and Vibrio 
infections(3,8,28,37,38). 
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Chapter 7 
 
 
 
 
 
 
 
 
Conclusions and future directions 
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7.1.0. Conclusions 
The significant variables that predict morbidity in patients with soft tissue infections are 
1. Neutrophilia in differential count with a p value of 0.079. 
2. Low sodium with a p value of 0.008. 
3. Elevated temperature at presentation with a p value of 0.029. 
 
The significant variables that predict mortality in patients with soft tissue infections are  
1. Diabetes mellitus as a co morbid illness with a p value of 0.014. 
2. Requirement of ventilator support with a p value of 0.000. 
3. Requirement of dialysis with a p value of 0.026. 
 
 
 
7.2.0. Future direction: 
Based on the factors predicting mortality and morbidity in soft tissue infection, a scoring system is to be 
devised. Further studies are required for the validation of the scoring system.  
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     9.1.0. Annexure 1 
Pro forma for data collection 
  Christian Medical College, Vellore 
 Department of General Surgery 
An Observational study on factors predicting mortality and morbidity in patients with soft tissue 
infections 
Proforma for Data Collection 
 
Serial number:    Hospital number:    Place: 
 
Name:      Age:   Sex:                      Occupation: 
 
Time of onset of problem (onset to hospital admission): 
 
Type of onset: Traumatic [  ]           Insect bite [  ]              Spontaneous [  ]        Surgical [  ] 
 
Previous co morbid illness: 
 
Number of co morbid illness: 
 
Hr:    B.P:   R.R:  Temperature:  GCS: 
 
Oedema:   Icterus:           Swelling:                   Haemorrhagic Bullae 
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Peripheral pulses:      left   right 
  Femoral 
  Popliteal 
  Dorsalis pedis 
 
Haemoglobin:   Total counts:    Differential counts: 
 
Platelet :    Pt/INR:   APTT: 
 
Creatinine:   Urea:    Sodium:   Potassium: 
 
Calcium:   Albumin:   Glucose: 
 
Bicarbonate:  Lactate:   Base excess:  Anion gap: 
 
Saturation:      P/F ratio: 
 
Procalcitonin:      Serum Myoglobin: 
 
Tissue culture: 
  Organisms: 
 
  Sensitivity: 
Blood Culture: 
  Organisms: 
 
  Sensitivity: 
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Debridement:    Number of times of debridement 
 
Time taken for intervention:      Amputation: 
 
Ventilation:     Number of days in ventilator 
 
Inotropes:     Number of days on inotropes: 
 
Myocardial infarct: 
 
Renal failure:     Need for dialysis: 
 
Number of days of hospital stay: 
 
Mortality: 
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 9.2.0. Annexure 2 
Patient information sheet 
      Christian Medical College, Vellore 
                                                 Department of General Surgery 
An Observational study on factors predicting mortality and morbidity in patients with soft tissue 
infections 
                                                           Information sheet 
 
You are invited to be part of a study to improve the current knowledge about your disease 
condition. This study will help other patients who later come to hospital with the same complaints.  
By agreeing to be a part of this study, you will contribute to recognizing early how severe the 
disease is and thereby starting appropriate treatment immediately. The severity of your disease 
and the final treatment received will be compared to the information collected from you in the 
beginning.  
The information collected from you will include 
1. History – This includes details regarding your general health and the present illness 
2. Clinical examination – Includes evaluation by the attending doctor on admission to the 
hospital 
3. Investigations – Includes the results of relevant blood and urine tests 
Whether you accept or decline to be a part of this study will not affect your further treatment at 
this hospital. 
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The benefits of joining in this study will be that you don’t have to pay for a particular laboratory 
test which is called “arterial blood gas”. The money for this particular test alone will be provided 
by the study team.  
There is no disadvantage or complication that can happen to you by participating in this study as 
this study does not interfere in the treatment provided by the caretaker. 
All details including personal data, assessment of the doctor during and after the operation will be 
kept confidential. 
We aim to include about 150 people from this hospital in this study in the next 2 years. 
Participation in this study is purely voluntary, and you can withdraw from the study at any time 
and that refusal to participate will not involve any penalty or loss of benefits to which you are 
otherwise entitled. 
In case of doubts/ questions, please contact Dr. Vijayan P, Dept of General Surgery, CMCH Vellore. 
Ph no: +919840529964 
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     9.3.0. Annexure 3 
Patient consent form 
Informed Consent form to participate in a clinical trial 
Christian Medical College, Vellore 
Department of General Surgery 
An Observational study on factors predicting mortality and morbidity in patients with soft tissue 
infections 
Study Number: 
Subject’s Initials: _________ Subject’s Name: ________ 
Date of Birth / Age: _______ 
Please initial box  
(i) I confirm that I have read/been read to and understood the information sheet dated _________ for the 
above study and have had the opportunity to ask questions. [ ] 
(ii) I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time, without giving any reason, without my medical care or legal rights being 
affected. [ ] 
 (iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s behalf, the Ethics 
Committee and the regulatory authorities will not need my permission to look at my health records both 
in respect of the current study and any further research that may be conducted in relation to it, even if I 
withdraw from the trial. I agree to this access. However, I understand that my identity will not be revealed 
in any information released to third parties or published. [ ] 
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(iv) I agree not to restrict the use of any data or results that arise from this study provided such a 
use is only for scientific purpose(s) [ ] 
(v) I agree to take part in the above study. [ ] 
Signature (or Thumb impression) of the Subject/Legally Acceptable Representative: _____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
Signature of the Witness: ___________________________ 
Date: _____/_____/_______ 
Name of the Witness: ______________________________ 
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9.4.0. Annexure 4 
Data sheet 
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